Johnson & Johnson (NYSE:JNJ) Shares Purchased by Prentice Wealth Management LLC

Prentice Wealth Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the fourth quarter, Holdings Channel reports. The fund owned 5,587 shares of the company’s stock after purchasing an additional 240 shares during the period. Prentice Wealth Management LLC’s holdings in Johnson & Johnson were worth $808,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. IFS Advisors LLC boosted its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $35,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $32,000. Finally, Activest Wealth Management purchased a new position in Johnson & Johnson in the third quarter worth $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Wolfe Research began coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Stifel Nicolaus lowered their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Leerink Partners reduced their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Bank of America decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Finally, Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $166.13 on Wednesday. The firm has a market cap of $399.98 billion, a P/E ratio of 24.98, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a 50-day simple moving average of $149.72 and a 200-day simple moving average of $155.92.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.29 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 2.99%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.